The tools to end new HIV infections and AIDS exist. The knowledge on how to use them is agreed upon. Nevertheless late diagnosis of HIV remains a challenges across the European Union and European Economic Area.
From diagnosis of HIV to successful viral suppression: in a rapid communication published in Eurosurveillance, ECDC and co-authors from Public Health England and The National AIDS Trust summarise the progress towards HIV elimination in 52 countries in Europe and Central Asia. The main issues: diagnosing those who are unaware of their HIV infection and treating them.
With nearly 160 000 people newly diagnosed with HIV, 2017 marked another year of alarming numbers of new HIV diagnoses in the WHO European Region. In contrast, the European Union and European Economic Area (EU/EEA) countries reported a decline in rates of new diagnoses, mainly driven by a 20% decrease since 2015 among men who have sex with men.
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.